Announcement on Relocation of Company Office Premises
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Relocation of Company Office Premises
Filed with SSE ·
6ix hasn’t read this filing yet.
Ningbo Menovo Pharmaceutical Co., Ltd. on 6ix
Earlier from Ningbo Menovo Pharmaceutical
- Announcement on the Holding Subsidiary Re-certified as High-tech Enterprise
- Announcement on Expected Increase in Performance for 2025
- Announcement on the Subsidiary Re-certified as High-tech Enterprise
- Notice on Convening the 1st Extraordinary General Meeting in 2026
- Announcement on Wholly-owned Subsidiary Obtaining Drug Registration Certificate for Adempas Riociguat Tablets
Later from Ningbo Menovo Pharmaceutical
- Announcement on Not Revising the Downward Conversion Price of "Menovo Convertible Bonds"
- Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stocks
- Announcement on Selection of Products of the Wholly-owned Subsidiary for Continuation Procurement Under National Procurement Scheme After Agreement Expiry
- Indicative Announcement on the Completion of Cancellation of Repurchased Shares and Passive Change in Equity of Shareholder with Over 5% Shares Reaching an Integral Multiple of 1%
- Announcement on Abnormal Fluctuation of Convertible Bond Trading and Risk Warning in Stock Trading
Follow Ningbo Menovo Pharmaceutical into a list and get an email when it puts out news.
Follow Ningbo Menovo Pharmaceutical